Chronic Hives That Don’t Respond to Antihistamines

0
0

When standard-dose antihistamines leave symptoms uncontrolled, chronic hives treatment usually follows a stepwise path: confirm that the symptoms fit chronic spontaneous urticaria (CSU), increase a second-generation antihistamine if appropriate, then consider omalizumab and specialist options. A lack of response does not mean you have missed a hidden food allergy; CSU often has no identifiable external trigger.

How Clinicians Confirm Chronic Hives

Urticaria is considered chronic when wheals (raised, itchy welts), angioedema (deeper swelling), or both recur for more than six weeks. In CSU, symptoms arise without a consistent, identifiable trigger. A clinician usually starts with your history and an examination: when the rash appears, what it looks and feels like, whether swelling occurs, and what medicines or circumstances seem related. Photos and a symptom diary can help describe episodes between appointments.

The assessment also checks whether another condition better explains the symptoms. Hives reliably brought on by cold, pressure, heat, or another stimulus may point to chronic inducible urticaria. Clinicians may consider other mimics, including urticarial vasculitis or hereditary angioedema, when the pattern suggests them. Tests are chosen to answer a specific clinical question rather than ordered as a broad screening panel.

Routine broad allergy testing is usually unhelpful for CSU because the condition is not generally driven by a single, reproducible allergen. Testing may make sense when your history points to a particular allergic reaction, but a wide panel can produce results that do not explain ongoing spontaneous hives. If a suspected food or exposure has no clear, repeatable connection to symptoms, discuss that uncertainty with your clinician before making major restrictions.

Chronic Hives Treatment: The Usual Next Steps

1. Review the antihistamine plan. Second-generation H1 antihistamines are the usual first treatment. Your clinician may check that you are taking the medicine regularly and consider increasing the dose of the same antihistamine, in steps, up to four times its standard dose. This approach is recommended in international guidance when symptoms remain uncontrolled; higher doses may be off-label, so do not increase your dose without medical advice. Some people improve, but others still have symptoms.

2. Consider omalizumab. If symptoms persist despite a higher-dose antihistamine, omalizumab (sold as Xolair) is a commonly recommended add-on. It is an injection that targets immunoglobulin E (IgE), a part of the immune pathway involved in CSU. It is not an allergy test or a treatment reserved only for people with high IgE levels.

A real-world study by Shuayb Elkhalifa and colleagues at Cleveland Clinic Abu Dhabi followed 75 adults with CSU that had not responded to up to fourfold antihistamine doses. The study took place at the clinic in the United Arab Emirates from 2015 to 2018 and assessed symptom control before and after omalizumab. The researchers recorded complete responses in 84% of patients, partial responses in 13%, and poor responses in 3%; reported adverse events were infrequent and mild. These results are encouraging, but the study was retrospective and involved a relatively small group at one specialist clinic, so they cannot predict an individual patient’s response.

3. Ask about specialist options if control remains poor. A specialist may discuss treatments such as ciclosporin (also called cyclosporine), particularly when omalizumab is ineffective or unsuitable. These medicines need careful consideration and monitoring. Evidence for several alternatives is less robust than for omalizumab, so the choice depends on the person’s symptoms, health circumstances, and treatment risks. New or less-established approaches are not interchangeable with the usual treatment steps.

Why Long-Term Steroids Usually Aren’t the Answer

Oral corticosteroids may sometimes be used for a short course during a severe flare, but they are not a routine long-term CSU treatment. They can temporarily suppress symptoms without providing a sustainable plan for ongoing disease control, and prolonged use can cause significant harm. If you are relying on repeated courses, ask your clinician to review the diagnosis and discuss a longer-term strategy.

Access and Approval Depend on Where You Live

Omalizumab’s authorization, prescribing rules, coverage, and cost vary by country and health system. The US FDA approved it as an add-on for antihistamine-refractory urticaria in 2014; Korean approval followed in 2017. UK NICE guidance recommends it for people whose CSU has not responded to high-dose antihistamines, but local eligibility and funding rules still matter. Ask your clinician or insurer what criteria apply where you live. For more background on the diagnosis and treatment of chronic spontaneous urticaria, see our related guide.

Because hives and swelling can have different causes, a clinician should guide changes to treatment. Seek emergency help if swelling affects your tongue or throat or you have difficulty breathing.